Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2015-12-28
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects, who require treatment with liraglutide

Exclusion Criteria:

• Subjects who are or have previously been on liraglutide

• Subjects who have previously been enrolled in the study

• Subjects with a hypersensitivity to liraglutide or to any of the excipients

• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods

• Subjects with cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder, except for conditions associated with type 2 diabetes mellitus history which in the physicians' opinion could interfere with the results of the trial

• Known or suspected abuse of alcohol or narcotics